| 11:00 | 395 | PURE: Patterns of risk factor prevalence for CVD globally by urbanization, gender, and economic status of countries and individuals: The Prospective Urban Rural Epidemiologic (PURE) Study of 153,996 people from 628 communities in 17 countries | Salim YUSUF (Hamilton, CA) |
|
| 11:10 | 396 | Discussant: PURE: Patterns of risk factor prevalence for CVD globally by urbanization, gender, and economic status of countries and individuals: The Prospective Urban Rural Epidemiologic (PURE) Study of 153,996 people from 628 communities in 17 countries | David Allan WOOD (London, GB) |
|
| 11:15 | 397 | DeFACTO: Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography | James MIN (Los Angeles, US) |
|
| 11:25 | 398 | Discussant: DeFACTO: Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography | Jean-Pierre BASSAND (Thise, FR) |
|
| 11:30 | 399 | ALTITUDE: ALiskiren Trial In Type 2 Diabetes Using cardio-renal Endpoints | Hans Henrik PARVING (Copenhagen, DK) |
|
| 11:40 | 400 | Discussant: ALTITUDE: ALiskiren Trial In Type 2 Diabetes Using cardio-renal Endpoints | Johannes MANN (Munchen, DE) |
|
| 11:45 | 401 | TRILOGY-ACS: Prasugrel versus clopidodrel for patients with Unstable Angina/NSTEMI who are medically managed without revascularization | Matthew ROE (Durham, US) |
|
| 11:55 | 402 | Discussant: TRILOGY-ACS: Prasugrel versus clopidodrel for patients with Unstable Angina/NSTEMI who are medically managed without revascularization | Raffaele DE CATERINA (Chieti, IT) |
|
| 12:00 | 403 | PARAMOUNT: Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Patients with Heart Failure and Preserved Ejection Fraction: Primary Results from the PARAMOUNT Study | Scott SOLOMON (Boston, US) |
|
| 12:10 | 404 | Discussant: PARAMOUNT: Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Patients with Heart Failure and Preserved Ejection Fraction: Primary Results from the PARAMOUNT Study | Piotr PONIKOWSKI (Wroclaw, PL) |
|
| 12:15 | 405 | Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure | Burkert Mathias PIESKE (Graz, AT) |
|
| 12:25 | 406 | Discussant: Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure | John CLELAND (Kingston Upon Hull, GB) |
|